Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HK2 | P52789 | 4/20 | 0.39 |
| ▸ | HK1 | P19367 | 3/20 | 0.39 |
| ▸ | PYGB | P11216 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27613884 | 1.00 | KDM4E (0.46) | KDM4ELMNACYP2D6CYP2C19MAPK1 | |
| SCHEMBL12009770 | 0.85 | MAPK1 (0.40) | KDM4ELMNACYP2D6CYP2C19MAPK1 | |
| SCHEMBL31237116 | 0.82 | KDM4E (0.48) | KDM4ELMNACYP2D6CYP2C19MAPK1 | |
| SCHEMBL28081071 | 0.78 | KDM4E (0.44) | KDM4ELMNACYP2D6CYP2C19MAPK1 | |
| SCHEMBL27718308 | 0.77 | PYGB (0.55) | PYGBGAACA1CA2CA9 | |
| SCHEMBL27436577 | 0.77 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19MAPK1 | |
| SCHEMBL13026581 | 0.77 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19MAPK1 | |
| SCHEMBL15871968 | 0.77 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19MAPK1 | |
| SCHEMBL1101428 | 0.77 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19MAPK1 | |
| SCHEMBL13067603 | 0.77 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176696-A1 | Methods And Compositions For Modulating An Immune Response | THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176696-A1 | Methods And Compositions For Modulating An Immune Response | IL5, IL4, IL2 | KDM4E 1949/4885LMNA 4298/4885CYP2D6 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.